506058363 05/13/2020

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6105077

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
ZEREN WANG	09/18/2017
JUN XU	09/18/2017

RECEIVING PARTY DATA

Name:	SHENZHEN HLK PHARMACEUTICALS CO., LTD.		
Street Address:	ress: 10 GAOXIN CENTRAL 1ST AVE		
Internal Address:	nternal Address: SUITE 1-303, BIO-INCUBATOR, NANSHAN DISTRICT		
City:	GUANGDONG PROVINCE, SHENZHEN		
State/Country:	CHINA		
Postal Code:	518057		

PROPERTY NUMBERS Total: 2

Property Type	Number
Application Number:	16554103
Application Number:	16554112

CORRESPONDENCE DATA

Fax Number: (650)493-6811

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: (650) 493-9300

Email: patentdocket@wsgr.com, bmaclean@wsgr.com **Correspondent Name:** WILSON SONSINI GOODRICH & ROSATI

Address Line 1: 650 PAGE MILL ROAD

Address Line 4: PALO ALTO, CALIFORNIA 94304-1050

ATTORNEY DOCKET NUMBER: 54758-702.302 AND 303	
NAME OF SUBMITTER:	YING CHEN
SIGNATURE:	/Ying Chen/
DATE SIGNED:	05/13/2020

Total Attachments: 4

source=702302and303#page1.tif source=702302and303#page2.tif source=702302and303#page3.tif

> **PATENT** REEL: 052652 FRAME: 0734 506058363

source=702302and303#page4.tif

PATENT REEL: 052652 FRAME: 0735

ASSIGNMENT

I, Zeren WANG, having a residence at 10 Gaoxin Central 1st Ave, Suite 1-303, Bio-incubator, Nanshan District, Guangdong Province, Shenzhen 518057, China;

I, Jun XU, having a residence at 10 Gaoxin Central 1st Ave, Suite 1-303, Bioincubator, Nanshan District, Guangdong Province, Shenzhen 518057, China; and

I, Long QU, having a residence at 10 Gaoxin Central 1st Ave, Suite 1-303, Bio-incubator, Nanshan District, Guangdong Province, Shenzhen 518057, China;

(hereinafter "ASSIGNORS") in consideration of the sum of Ten Dollars (\$10.00), or the equivalent thereof, and other good and valuable consideration, the sufficiency of which and receipt of which are hereby acknowledged, paid to ASSIGNORS by

Shenzhen HLK Pharmaceuticals Co., Ltd.

a Corporation having a place of business at 10 Gaoxin Central 1st Ave, Suite 1-303, Bio-incubator, Nanshan District, Guangdong, Shenzhen 518057, China (hereinafter "ASSIGNEE"), do hereby sell and assign to said ASSIGNEE, its successors and assigns, the below indicated right, title, and interest, **throughout the world** in and to our Invention entitled:

A PHARMACEUTICAL FORMULATION OF PALBOCICLIB AND A PREPARATION METHOD THEREOF

invented by us and described in the U.S. Application No. 15/613,853, filed on June 5, 2017, International Application No. PCT/CN2016/086546, filed June 21, 2016 and CN 201610187046.8, filed March 29, 2016 by the above title and docket number in the United States of America; and all patents, divisions, reissues, continuations, continuations-in-part and any extensions thereof and rights of priority therein, said interest being our entire ownership interest in the same, to be held and enjoyed by said ASSIGNEE, its successors, assigns, or other legal representatives, to the full end of the term thereof, as fully and entirely as the same would have been held and enjoyed by us if this assignment and sale had not been made, including all rights of Assignor to recover for past infringement thereof;

PATENT REEL: 042659 FRAME: 0294

And for the consideration aforesaid, we hereby covenant and agree to and with said ASSIGNEE, its successors and assigns, that whenever ASSIGNEE, its counsel or representative, or the counsel or representative of its successors or assigns, shall advise that an amendment to, or a division of, or any other proceeding or action in connection with an application concerning said Invention, including interference proceedings, is lawful and desirable, or that a reissue or continuation or extension of such application or patent issuing therefrom is lawful and desirable, we will sign all papers and drawings, take all rightful oaths and affidavits, and do all acts necessary or required to be done for the procurement of all lawful rights associated with the Invention, or for the reissue or continuation or extension of the same, will do all acts necessary or required to secure in said ASSIGNEE, its successors or assigns, the title to and full benefit of all rights hereby assigned, without charge to said ASSIGNEE or its successors or assigns, but at its or their expense; and we hereby appoint every present or future officer of said ASSIGNEE as our agent to sign all such papers and to do all such necessary acts on our behalf, to the fullest extent permitted by law;

And we hereby authorize and request the Commissioner of Patents and Trademarks and any other granting authority to issue any Letters Patent resulting from said Invention and application(s) concerning same to said ASSIGNEE.

This assignment shall have an effective date corresponding to the last date of execution.

We declare under penalty of perjury under the laws of the United States of America, and under penalty of the laws of any other jurisdiction before which this document may be presented, that we have signed this document as our own free act and that all of the foregoing is true and correct.

2

PATENT REEL: 042650 FRAME: 0295

Dated: <u>Sept. 18. 2017</u>

Witness: Cloxis. Canz

Dated: Sept 18, 2017

Dated: Sept 18, 2017

Witness: Cloris, Cane

Dated: Sept 18, 2017

Dated: Soft 28. 2017

Witness: Closes. cang

Dated: 500+ 28, 2017

18. A

F

Long O

Jun XU

ACCEPTANCE BY ASSIGNEE

In connection with an assignment in any jurisdiction in which an acceptance by ASSIGNEE is required, I hereby accept this assignment on behalf of Shenzhen HLK. Pharmaceuticals Co., Ltd. I declare under penalty of perjury under the laws of the United States of America, and under penalty of the laws of any other jurisdiction before which this document may be presented, that (check all that apply):

X	I am an officer of the above-ic	dentified ASSIGNEE	
	I have signed this document on ASSIGNEE.	behalf of ASSIGNE	E with the full authority of the
	and that all the foregoing is tre	ue and correct.	
Dated:	Sept 18, 2017	Ву:	+
	Į.	Name:	JUN X4

Title:

CEO